Randomized, Three Period Cross Over, Double Blind, Double Dummy Study in Type 2 Diabetic Patients to Assess the Endothelial Effects of Linagliptin, Glimepiride and Placebo Therapy for 28 Days ('ENDOTHELINA')

Trial Profile

Randomized, Three Period Cross Over, Double Blind, Double Dummy Study in Type 2 Diabetic Patients to Assess the Endothelial Effects of Linagliptin, Glimepiride and Placebo Therapy for 28 Days ('ENDOTHELINA')

Completed
Phase of Trial: Phase I

Latest Information Update: 18 Sep 2015

At a glance

  • Drugs Linagliptin (Primary) ; Glimepiride
  • Indications Type 2 diabetes mellitus
  • Focus Pharmacodynamics
  • Acronyms ENDOTHELINA
  • Sponsors Boehringer Ingelheim; Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 22 Jan 2014 According to ClinicalTrials.gov record study status changed from active, no longer recruiting to completed.
    • 18 Sep 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 08 Aug 2013 Planned end date changed from 1 Nov 2013 to 1 Jan 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top